IBRX Christobel Selecky sells $188K worth of shares
Feb 01, 2026, 5:35 AM
0.00%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
Christobel Selecky sold 25,000 shares of IBRX on 20 January at $7.51 per share, worth a total of $188K. They now own 0 IBRX shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.